Sumitomo Pharma
Sumitomo Pharma Co., Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1897, the company has a rich history marked by significant milestones, including advancements in research and development that have positioned it as a leader in innovative healthcare solutions. Specialising in prescription pharmaceuticals, Sumitomo Pharma focuses on areas such as central nervous system disorders, oncology, and regenerative medicine. Its unique approach to drug development, emphasising both quality and efficacy, has led to the creation of several groundbreaking therapies. With a strong market presence and a commitment to improving patient outcomes, Sumitomo Pharma continues to achieve notable recognition within the industry, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Sumitomo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sumitomo Pharma's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sumitomo Pharma's reported carbon emissions
In 2023, Sumitomo Pharma Co., Ltd. reported significant carbon emissions, with Scope 2 emissions amounting to approximately 26,827,000 kg CO2e and Scope 3 emissions reaching about 356,214,000 kg CO2e. The Scope 3 emissions breakdown includes substantial contributions from purchased goods and services (approximately 305,002,000 kg CO2e) and capital goods (about 18,623,000 kg CO2e). Sumitomo Pharma has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2020 as the baseline. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions from purchased goods and services within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are classified under the 1.5°C pathway, reflecting the company's commitment to mitigating climate change. The emissions data is cascaded from Sumitomo Pharma Co., Ltd., which operates as a current subsidiary within its corporate family. The company has not yet committed to a net-zero target but continues to enhance its sustainability efforts in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 41,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 38,906,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 35,270,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sumitomo Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
